Page 44 - MemoriaCIBER-2018ENG

44
risk factors and cardiovascular risk functions, progress has been made in several important projects in 2018. In the evaluation of the magnitude of the problem of cardiovascular disease, data has been obtained on the population incidence
of acute myocardial infarction in the population >35 years on the prevalence of obesity in Spain. At present data on over 3 million people is being analysed.
Regarding the risk factors associated
with the development of cardiovascular diseases, several risk factors connected with ischaemic cardiopathy have been identified, helping to improve predictive capacity. An analysis has been made of the importance of sleep and adherence to healthy lifestyles in cardiovascular risk.
Increasing knowledge in the clinical epidemiology of acute myocardial infarction and coronary syndromes
in Spain is a very relevant part of the programme. In 2018, several hospital registers (SPARTA and ATHOS) in which 15 CIBERCV centres take part analysed anti- platelet treatment at 18 months in patients with ACS, the variability in treatment between centres and the prognosis of these patients. It is being analysed whether the generic information may help to identify patients with a worse prognosis.
The CORDELIA project has also been got under way,including 30 INTER-CIBER groups in this collaborative study of cohorts, with over 170,000 participants and biological samples of around 100,000. The nucleic
Molecular and imaging biomarkers and precision CV medicine
Coordinator:
Javier Díez
CIBERCV Programme 4 is intended for the identification, validation and translation to the National Health System of molecular and imaging biomarkers, enabling early and accurate diagnosis of cardiovascular
database is expected to be ready during summer 2019. This database will constitute the greatest biobank of the general population and of patients with Myocardial Infarction existing to date in this country.
As regards knowledge transfer, an adaptation of the REGICOR function
for patients with HIV is being validated, analysing whether this population
has a greater prevalence of factors of cardiovascular risk than the general population.
Furthermore, in the approach
covering genetics and mechanisms
of arteriosclerosis, progress has been made in 2018 with identifying genetic variants connected with ictus, coronary disease, high blood pressure, familial hyperlipidaemia and other cardiovascular phenotypes. An analysis has been made of the epigenetics of cardiovascular disease by means of a study of the methylation of DNA and miRNA. The findings were published in Nature Genetics, Nature Communications, Circulation, Stroke, ATVB, Atherosclerosis.
More specifically,we have used genetic information as an instrumental variable
to analyse the causal relationship between soluble receptor LRP1 and characteristics of HDL, and heart disease. It has been shown that genetic biomarkers help to improve the prediction of classic risk functions and an online platform is being designed to facilitate access to the results of genomic studies in cardiovascular disease.
pathologies, for their personalised and effective treatment.
The line of research focussing on the evaluation of known biomarkers, coordinated by Dr Antoni Bayés-Genís,
has made some major progress. In the
field of heart failure, we should stress the validation of sST2 as a biomarker of clinical utility. IL-1b has also been identified as a prognostic biomarker in the setting of acute heart failure. With regard to the guide for treatment, the clinical utility of CA125 has been proven. Lastly, a recently identified molecule in a Line 2 project, IGFBP2, has been validated as a prognostic biomarker. In the field of heart disease, we should stress
CIBERCV | ANNUAL REPORT 2018